These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37352285)

  • 1. Mass spectrometry imaging of hair identifies daily maraviroc adherence in HPTN 069/ACTG A5305.
    Rosen EP; White N; Gilliland WM; Gerona RR; Gandhi M; Amico KR; Mayer KH; Gulick RM; Kashuba ADM
    PLoS One; 2023; 18(6):e0287449. PubMed ID: 37352285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infrared Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging of Human Hair to Characterize Longitudinal Profiles of the Antiretroviral Maraviroc for Adherence Monitoring.
    Gilliland WM; Prince HMA; Poliseno A; Kashuba ADM; Rosen EP
    Anal Chem; 2019 Aug; 91(16):10816-10822. PubMed ID: 31345022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass Spectroscopy Imaging of Hair Strands Captures Short-Term and Long-Term Changes in Emtricitabine Adherence.
    Mwangi JN; Gilliland WM; White N; Sykes C; Poliseno A; Knudtson KA; Hightow-Weidman L; Kashuba ADM; Rosen EP
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0217621. PubMed ID: 35266824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Antiretrovirals in Single Hair Strands for Evaluation of Drug Adherence with Infrared-Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging.
    Rosen EP; Thompson CG; Bokhart MT; Prince HM; Sykes C; Muddiman DC; Kashuba AD
    Anal Chem; 2016 Jan; 88(2):1336-44. PubMed ID: 26688545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of hair treatments on detection of antiretrovirals by mass spectrometry imaging.
    Gilliland WM; White NR; Yam BH; Mwangi JN; Prince HMA; Weideman AM; Kashuba ADM; Rosen EP
    Analyst; 2020 Jul; 145(13):4540-4550. PubMed ID: 32420552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305).
    Mayer KH; Yuhas K; Amico KR; Wilkin T; Landovitz RJ; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Cottle LM; Marcus C; Chege W; Rinehart AR; Rooney JF; Andrew P; Salata RA; Magnus M; Farley JE; Liu AY; Frank I; Ho K; Santana J; Stekler JD; Chen YQ; McCauley M; Gulick RM;
    AIDS Behav; 2022 Dec; 26(12):4107-4114. PubMed ID: 35687192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).
    Gulick RM; Wilkin TJ; Chen YQ; Landovitz RJ; Amico KR; Young AM; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; McGowan I; Cottle LM; Andrade A; Marcus C; Klingman KL; Chege W; Rinehart AR; Rooney JF; Andrew P; Salata RA; Magnus M; Farley JE; Liu A; Frank I; Ho K; Santana J; Stekler JD; McCauley M; Mayer KH
    J Infect Dis; 2017 Jan; 215(2):238-246. PubMed ID: 27811319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.
    Koss CA; Hosek SG; Bacchetti P; Anderson PL; Liu AY; Horng H; Benet LZ; Kuncze K; Louie A; Saberi P; Wilson CM; Gandhi M
    Clin Infect Dis; 2018 Jan; 66(2):213-219. PubMed ID: 29020194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.
    Thaden JT; Gandhi M; Okochi H; Hurt CB; McKellar MS
    AIDS; 2018 Jun; 32(9):F1-F4. PubMed ID: 29683856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.
    McGowan I; Wilkin T; Landovitz RJ; Wu C; Chen Y; Marzinke MA; Hendrix CW; Richardson P; Eshleman SH; Andrade A; Chege W; Anderson PL; McCauley M; Farley J; Mayer KH; Anton P; Brand RM; Cranston RD; Gulick R
    AIDS; 2019 Feb; 33(2):237-246. PubMed ID: 30557160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen.
    Gandhi M; Murnane PM; Bacchetti P; Elion R; Kolber MA; Cohen SE; Horng H; Louie A; Kuncze K; Koss CA; Anderson PL; Buchbinder S; Liu A
    AIDS; 2017 Oct; 31(16):2245-2251. PubMed ID: 28832411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
    Liu AY; Yang Q; Huang Y; Bacchetti P; Anderson PL; Jin C; Goggin K; Stojanovski K; Grant R; Buchbinder SP; Greenblatt RM; Gandhi M
    PLoS One; 2014; 9(1):e83736. PubMed ID: 24421901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
    Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring.
    Koss CA; Liu AY; Castillo-Mancilla J; Bacchetti P; McHugh C; Kuncze K; Morrow M; Louie A; Seifert S; Okochi H; MaWhinney S; Gandhi M; Anderson PL
    AIDS; 2018 Sep; 32(15):2189-2194. PubMed ID: 30212404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence Measurements in HIV: New Advancements in Pharmacologic Methods and Real-Time Monitoring.
    Castillo-Mancilla JR; Haberer JE
    Curr HIV/AIDS Rep; 2018 Feb; 15(1):49-59. PubMed ID: 29380227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.
    Gulick RM; Wilkin TJ; Chen YQ; Landovitz RJ; Amico KR; Young AM; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; McGowan I; Cottle LM; Andrade A; Marcus C; Klingman KL; Chege W; Rinehart AR; Rooney JF; Andrew P; Salata RA; Siegel M; Manabe YC; Frank I; Ho K; Santana J; Stekler JD; Swaminathan S; McCauley M; Hodder S; Mayer KH
    Ann Intern Med; 2017 Sep; 167(6):384-393. PubMed ID: 28828489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions.
    Spinelli MA; Haberer JE; Chai PR; Castillo-Mancilla J; Anderson PL; Gandhi M
    Curr HIV/AIDS Rep; 2020 Aug; 17(4):301-314. PubMed ID: 32424549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT.
    Velloza J; Bacchetti P; Hendrix CW; Murnane P; Hughes JP; Li M; Curlin ME; Holtz TH; Mannheimer S; Marzinke MA; Amico KR; Liu A; Piwowar-Manning E; Eshleman SH; Dye BJ; Gandhi M; Grant RM;
    J Acquir Immune Defic Syndr; 2019 Oct; 82(2):149-158. PubMed ID: 31335588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis.
    Ibrahim ME; Castillo-Mancilla JR; Yager J; Brooks KM; Bushman L; Saba L; Kiser JJ; MaWhinney S; Anderson PL
    AIDS Res Hum Retroviruses; 2021 Jun; 37(6):421-428. PubMed ID: 33191774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.